Bulletin
Investor Alert

New York Markets Open in:

Sept. 23, 2022, 8:52 a.m. EDT

Mental Health Claims up 75% Since 2019

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Numinus Wellness Inc. (NUMI)
  • X
    HCA Healthcare Inc. (HCA)
  • X
    Sage Therapeutics Inc. (SAGE)

or Cancel Already have a watchlist? Log In

Sep 23, 2022 (Financial News Media via COMTEX) -- FN Media Group Presents Microsmallcap.com Market Commentary

New York, NY - September 23, 2022 – Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75% from 2019 as more Canadians tapped into their mental health benefits. According to the Canadian Life and Health Insurance Association (CLHIA) president and CEO, 2021 was a year of recovery, making mental health support increasingly important. Despite rising demand for mental health care, only 19% of companies in Canada increased their maximum coverage for mental health last year. Luckily, that seems to be changing with several employers beginning to expand their offerings. At the same time, increased awareness surrounding mental wellness is creating an opportunity for companies like Numinus Wellness /zigman2/quotes/202854807/delayed CA:NUMI 0.00% (otcqx:NUMIF), HCA Healthcare /zigman2/quotes/205934574/composite HCA +0.63% , Sage Therapeutics /zigman2/quotes/200179567/composite SAGE -2.33% , LifeStance Health Group /zigman2/quotes/227111452/composite LFST +1.07% , and Acadia Healthcare /zigman2/quotes/208646495/composite ACHC -3.27% to shine.

Numinus Wellness Inc. /zigman2/quotes/202854807/delayed CA:NUMI 0.00% (otcqx:NUMIF) is a mental health care company focused on advancing innovative mental health care and safe, evidence-based psychedelic-assisted therapies. Numinus offers a wide range of mental healthcare services, from counseling and therapy to Transcranial Magnetic Stimulation (TMS) to Ketamine-assisted therapy and psychedelic-assisted therapy through Canada’s Special Access Program (SAP).

Numinus has continued to expand its network of clinics and currently operates 13 clinics across Canada and the United States.

On September 22, Numinus announced the opening of a new Montreal location to replace an existing downtown clinic. The new site will have expanded capacity to offer ketamine treatments, including different administrations of ketamine (Spravato, intramuscular, lozenge and nasal spray) and a wider variety of ketamine-assisted therapy options.

Right now, Numinus offers a six-week ketamine-assisted therapy program for the treatment of addiction, depression, anxiety and trauma. The new services will allow patients the option to receive ketamine as a standalone treatment to complement prior ketamine-assisted therapy and can be used as an emergency antidepressant or with therapy from an external health provider.

The company has also expanded its offerings at its Toronto clinic, the Neurology Centre of Toronto (NCT). NCT now offers Ketamine-assisted therapy for individuals with neurologic conditions, including brain injury, epilepsy, concussion, and functional neurological disorders.

NCT includes a team of over 20 specialists offering a comprehensive range of services including primary neurologic care and supportive therapies. The clinic's new ketamine-assisted therapy service will be led by a psychologist and follow existing protocol for such therapies, which are already being used at the company's other locations in the US and Canada.

"Following a thorough evaluation, Numinus found NCT’s existing infrastructure, client base and practitioners to be highly suitable for offering ketamine-assisted therapy. Mental health challenges are commonly associated with neurologic diagnoses and ketamine-assisted therapy is a promising tool that we now have available for our patients,” said Dr. Evan Lewis, VP of Psychedelic Neurology at Numinus.“The use of ketamine-assisted therapy within the field of neurology is novel, and we look forward to expanding access for our patients and contributing to the body of knowledge regarding ketamine applications.”

Numinus Wellness also revealed that NCT's expanded offering will also support applications for Health Canada’s Special Access Programme (SAP) for other psychedelic-assisted therapies. The SAP is a federal program that allows patients with serious or life-threatening conditions to apply for access to investigational medical treatments not yet available to the public, including therapies using psychedelics like MDMA and psilocybin.

Numinus Wellness also provided an update recently on the Novamind acquisition integration in the US. The company's newly acquired US clinics performed well in fiscal Q4, with a significant increase in customer appointments in recent months. Across August, nearly 6,200 customer appointments were held in Canada and the United States, a 25% increase over July. The company’s eight US wellness clinics – six in Utah and two in Arizona – completed over 4,900 customer appointments in August, a 22% increase over July.

Numinus is working to extend its Ketamine-assisted therapy product across Canada. Ketamine Therapy sessions jumped 35% from July to 1,520 visits in August at Numinus‘ US facilities. The demand for TMS services is also increasing. In August, the company conducted 725 TMS engagements, a 23% increase over the previous month.

For more information about Numinus Wellness /zigman2/quotes/202854807/delayed CA:NUMI 0.00% (otcqx:NUMIF), click here .

Research Continues In the Mental Health Field

HCA Healthcare /zigman2/quotes/205934574/composite HCA +0.63% announced that it will work with Johnson & Johnson to address critical healthcare industry issues. Improvements in patient outcomes, nursing assistance, and health equity will be the initial focus of the two top healthcare companies. HCA Healthcare continuously enhances treatment using information from more than 35 million patient visits annually. In addition, HCA Healthcare, one of the top employers of Registered Nurses (RNs) in the country with over 93,000 RNs, makes significant investments in nurses and the nursing profession through training and professional development, technology and equipment, and tools to support their physical and emotional wellbeing, and representation at all levels of the business, from the front lines to senior leadership.

Sage Therapeutics /zigman2/quotes/200179567/composite SAGE -2.33% is advancing a clinical program portfolio that includes internally discovered unique chemical entities that have the potential to become differentiated medications that improve brain health by targeting the GABAA and NMDA receptor systems. Many neurological and neuropsychiatric illnesses are thought to be caused by dysfunction in these systems. Sage stated that enrollment in the SUNBIRD Study, which examines the safe use of ZULRESSO as a therapy for PPD in a woman’s home, has concluded. In Q2 2022, net revenue from ZULRESSO sales was $1.5 million, compared to $1.6 million in the same time in 2021.

/zigman2/quotes/202854807/delayed
CA : Canada: Toronto
$ 0.22
0.00 0.00%
Volume: 246,064
Dec. 7, 2022 3:52p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$55.57 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/205934574/composite
US : U.S.: NYSE
$ 238.11
+1.49 +0.63%
Volume: 974,777
Dec. 7, 2022 4:00p
P/E Ratio
13.45
Dividend Yield
0.94%
Market Cap
$66.90 billion
Rev. per Employee
$210,563
loading...
/zigman2/quotes/200179567/composite
US : U.S.: Nasdaq
$ 40.64
-0.97 -2.33%
Volume: 627,955
Dec. 7, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.48 billion
Rev. per Employee
$13,724
loading...
/zigman2/quotes/227111452/composite
US : U.S.: Nasdaq
$ 5.69
+0.06 +1.07%
Volume: 376,936
Dec. 7, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.12 billion
Rev. per Employee
$123,614
loading...
/zigman2/quotes/208646495/composite
US : U.S.: Nasdaq
$ 81.94
-2.77 -3.27%
Volume: 1.09M
Dec. 7, 2022 4:00p
P/E Ratio
26.44
Dividend Yield
N/A
Market Cap
$7.71 billion
Rev. per Employee
$112,382
loading...
/zigman2/quotes/202854807/delayed
CA : Canada: Toronto
$ 0.22
0.00 0.00%
Volume: 246,064
Dec. 7, 2022 3:52p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$55.57 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/202854807/delayed
CA : Canada: Toronto
$ 0.22
0.00 0.00%
Volume: 246,064
Dec. 7, 2022 3:52p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$55.57 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/205934574/composite
US : U.S.: NYSE
$ 238.11
+1.49 +0.63%
Volume: 974,777
Dec. 7, 2022 4:00p
P/E Ratio
13.45
Dividend Yield
0.94%
Market Cap
$66.90 billion
Rev. per Employee
$210,563
loading...
/zigman2/quotes/200179567/composite
US : U.S.: Nasdaq
$ 40.64
-0.97 -2.33%
Volume: 627,955
Dec. 7, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.48 billion
Rev. per Employee
$13,724
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.